You are here: Industry Insights > Cosentyx

News List

China’s NMPA approves Novartis’ Cosentyx and Merck’s Keytruda pharmaceutical-technology
April 23, 2019
Novartis has announced that the Chinese National Medical Product Administration (NMPA) has approved its plaque psoriasis drug Cosentyx (secukinumab).
Novartis’ Cosentyx lands first-in-class Chinese psoriasis nod fiercepharma
April 10, 2019
Novartis’ psoriasis blockbuster Cosentyx has beaten out rivals from Eli Lilly and Johnson & Johnson as the first interleukin-17A inhibitor approved in China.
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasis pharmaphorum
December 14, 2018
A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
Plaque psoriasis study claims Tremfya superior to Cosentyx pharmatimes
December 13, 2018
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis' Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
Novartis Receives Approval for Cosentyx Label Update in Europe americanpharmaceuticalreview
October 30, 2018
Novartis Receives Approval for Cosentyx Label Update in Europe
China targets Cosentyx, Shingrix and Luxturna and 45 other drugs for priority approval fiercepharma
August 10, 2018
Hey, Big Pharma stars: China wants you. Aiming to speed new drugs to market, China just came up with a target list of 48 treatments greenlighted abroad, including some of the industry's biggest names.
Eli Lilly's Taltz pads case for a shot at Novartis' Cosentyx in ankylosing spondylitis fiercepharma
June 29, 2018
Eli Lilly’s Taltz is already up against Novartis’ immunology blockbuster Cosentyx in psoriasis and psoriatic arthritis. Now, Lilly looks poised to challenge the Swiss drugmaker in a third indication, too.
US approves joint damage data for Cosentyx pharmatimes
June 21, 2018
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
FDA approves label update of Cosentyx to include scalp psoriasis europeanpharmaceuticalreview
March 02, 2018
The FDA has approved a label update for Cosentyx, the first interleukin-17A inhibitor approved to treat moderate-to-severe plaque psoriasis…
Novartis looks past psoriasis for even bigger Cosentyx growth frontier fiercepharma
November 15, 2017
Novartis’ Cosentyx currently leads a crop of next-gen immunology products from a who’s who of Big Pharma. And the Swiss drugmaker intends to keep it that way.

Previous page 1 2 3 4 Next page